Since our founding in 1986, MAPS has disbursed over $12 million to developing psychedelics and marijuana into prescription medicines for some of the most hard-to-treat illnesses and to educating the public honestly about the risks and benefits of these substances.
Every dollar has come from private donors committed to our mission. The pharmaceutical industry, government agencies that support research, and major foundations have not yet supported our work, so the continued expansion of psychedelic research still relies on the generosity of individual donors.
Our top funding priorities are our studies of MDMA-assisted psychotherapy for chronic, treatment-resistant posttraumatic stress disorder (PTSD). These include our US study in veterans of war and our U.S. "intern" study, as well as our Israeli, Jordanian, and Canadian studies. For more information, see below, visit our MDMA research page, download our research prospectus, or visit www.mdmaptsd.org.
Our other ongoing research projects include LSD-assisted psychotherapy for end-of-life anxiety and ibogaine therapy for drug addiction. Our study of smoked or vaporized marijuana for PTSD in veterans is still seeking final regulatory approval. While most of our funding needs are for research, we also rely on your contributions for our educational mission and to maintain daily operations. None of this would be possible without your support. Donations can be restricted to specific projects or allocated to our general fund.
We are also seeking bequests, in addition to gifts of cash, stock, real estate, art, and other goods. Learn more about including MAPS in your will or trust.
MDMA-Assisted Psychotherapy Research Fund
LSD Psychotherapy Research Fund
Medical Marijuana Fund